Elektrofi, Thermo Fisher Reach Contract Manufacturing Agreement

Elektrofi, a biotechnology company focused on drug formulation and delivery services, has entered into an agreement with Thermo Fisher Scientific, a pharmaceutical equipment supplier. The deal aims to support clinical production of Elektrofi’s ultra-high concentration subcutaneous products.

The collaboration will facilitate the design of a platform current good manufacturing practice (cGMP) line—expected to be operational by early 2024—that supports early clinical efforts and enables scale-up for late-stage and commercial development. Created to navigate the challenges of delivering biologic-based therapies, this technology will reportedly allow patients to self-inject these therapies at home, as opposed to a hospital setting.

“ …We’re thrilled to partner with Thermo Fisher […] to meet this goal and continue advancing our efforts to change the way biologic-based drugs are delivered,” says Chase Hoffman, CEO and co-founder of Elektrofi. As previously alluded to, the company executive also notes that in order for clinical development to be successful, certified cGMP manufacturing capabilities need to be established.

Read more about the partnership here.